Volume 3.04 | Feb 3

Prostate Cell News 3.04, February 3, 2012
     In this issue: Publications | Science News | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Prostate Cell News on Twitter
TOP STORY

Activation of ß-Catenin Signaling in Androgen Receptor-Negative Prostate Cancer Cells
Researchers’ purpose was to study Wnt/ß-catenin in castrate-resistant prostate cancer and understand its function independently of the ß-catenin-androgen receptor interaction. [Clin Cancer Res] Abstract

Detect 7 times more prostate epithelial progenitors with ProstaCult

PUBLICATIONS (Ranked by Impact Factor of the Journal)

LABORATORY RESEARCH

LaminA/C Protein Is Overexpressed in Tissue-Invading Prostate Cancer and Promotes Prostate Cancer Cell Growth, Migration and Invasion through the Phosphoinositide 3-Kinase/AKT/PTEN Pathway
To characterize laminA/C’s function in prostate cancer cells, researchers performed a detailed expression analysis in prostate cancer tissue and explored the consequences of down or up-regulation of laminA/C in prostate cancer cells. [Carcinogenesis] Abstract


Preclinical Characterization of a Novel Diphenyl Benzamide Selective ERα Agonist for Hormone Therapy in Prostate Cancer

Scientists describe a novel nonsteroidal selective estrogen receptor-α agonist designed for first-line therapy of advanced prostate cancer that in animal models induces medical castration and minimizes many of the estrogen deficiency-related side effects of androgen deprivation therapy. [Endocrinology] Abstract


Casein Kinase 2 Inhibition Attenuates Androgen Receptor Function and Cell Proliferation in Prostate Cancer Cells

In this study, researchers tested the effects of tetra-bromo-cinnamic acid, a newly synthetic casein kinase 2 (CK2)-selective CK2 inhibitor, on androgen receptor transactivation, cell proliferation, and viability in multiple prostate cancer cell lines. [Prostate] Abstract


Autophagy Regulates Lipolysis and Cell Survival through Lipid Droplet Degradation in Androgen-Sensitive Prostate Cancer Cells

The objective of this study was to elucidate the function of autophagy in lipid droplet homeostasis and survival in androgen-sensitive prostate cancer cells. [Prostate] Abstract


Glycoprotein Transmembrane nmb: An Androgen-Downregulated Gene Attenuates Cell invasion and Tumorigenesis in Prostate Carcinoma Cells

Scientists suggest that the glycoprotein transmembrane nmb gene is a p53- and androgen-dysregulated gene and should be regarded as an anti-tumor gene for prostate cancer. [Prostate] Abstract


ProstaCaid™ Inhibits Tumor Growth in a Xenograft Model of Human Prostate Cancer

In the present study, researchers evaluated toxicity and whether ProstaCaid™ suppresses growth of prostate cancer in a xenograft model of human prostate cancer cells implanted in mice. [Int J Oncol] Abstract


The Anti-Obesity Drug Orlistat Promotes Sensitivity to TRAIL by Two Different Pathways in Hormone-Refractory Prostate Cancer Cells

Investigators report that the anti-obesity drug orlistat enhances the sensitivity to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in hormone-refractory prostate cancer cells through two different pathways. [Int J Oncol] Abstract


CLINICAL RESEARCH

High-Dose-Rate Brachytherapy and External-Beam Radiotherapy for Hormone-Naïve Low- and Intermediate-Risk Prostate Cancer: A 7-Year Experience
The purpose of this study was to report clinical outcomes and early and late complications in 264 hormone-naïve patients with low- and intermediate-risk prostate cancer treated with high-dose-rate brachytherapy in combination with external-beam radiotherapy. [Int J Radiat Oncol Biol Phys] Abstract


A Panel of Five Circulating MicroRNAs as Potential Biomarkers for Prostate Cancer

In this study, researchers investigated whether circulating microRNAs could be used in the diagnosis of prostate cancer in a Chinese patient population. [Prostate] Abstract


Effect of Treatment with 5-α Reductase Inhibitors on Progression in Monitored Men with Favorable-Risk Prostate Cancer

The objective of this study was to determine whether 5-α reductase inhibitor use delays cancer reclassification in an active surveillance cohort. [BJU Int] Abstract

50,000 scientists receive our newsletters. Do your colleagues? Click to share this newsletter now.

SCIENCE NEWS

Halozyme’s Ultrafast Insulin Formulations Improved Postprandial Glycemic Control in Patients Living with Type 1 Diabetes: Phase II Study Results
Data from the Phase II study indicated that the Company’s recombinant human hyaluronidase enzyme reduced postprandial glycemic excursions, as well as significantly reduced hypoglycemic events. [Press release from Halozyme Therapeutics, Inc. discussing research presented at the American Diabetes Association’s 72nd Scientific Sessions, Philadelphia] Press Release

Interim Data From Pre-administration of Hylenex in Analog Insulin Pump Therapy Demonstrate Consistent Insulin Action Profile
Halozyme Therapeutics, Inc. presented results from a Phase IV study of Hylenex® recombinant (hyaluronidase human injection) in sensor augmented insulin analog pump (SAP) therapy in patients living with Type 1 diabetes. [Press release from Halozyme Therapeutics, Inc. discussing research presented at the American Diabetes Association’s 72nd Scientific Sessions, Philadelphia] Press Release

Stem Cell Society Singapore (SCSS) 2012 Symposium: Stem Cell Based Therapy

INDUSTRY NEWS

NICE Consults on a New Treatment for Prostate Cancer
National Institute for Health and Clinical Excellence (NICE) has issued newdraft guidance not recommending the use of abiraterone (Zytiga, Janssen) in combination with prednisone or prednisolone for the treatment of castration-resistant metastatic prostate cancer that has progressed on or after docetaxel-containing therapy. [National Institute for Health and Clinical Excellence] Press Release


Grant Aids in Development of Screening Test
An East Carolina University researcher is developing a screening test for prostate cancer with help from a $50,000 grant from Triad Golfers Against Cancer. [East Carolina University] Press Release

POLICY NEWS
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
EVENTS

NEW Molecular Medicine Tri-Conference 2012
February 19-23, 2012
San Francisco, United States


NEW Keystone Symposia on Molecular and Cellular Biology: The Life of a Stem Cell: From Birth to Death
March 11-16, 2012
Olympic Valley, United States

JOB OPPORTUNITIES

Research and Development Technologist, hPSC Media (STEMCELL Technologies) 

Scientist – Pluripotent Stem Cells (STEMCELL Technologies)

Scientific Marketing Communications Specialist (STEMCELL Technologies Inc.)

Research Technologist, Manufacturing Sciences (STEMCELL Technologies)


Business Analyst – Product Management (STEMSOFT Software)

Clinical Research Associate (Jennerex Biotherapeutics, Inc.)

Research Associate – Development (Precision Therapeutics, Inc.)

Postdoctoral Research Fellow – Epidemiology / Prostate Studies (Fred Hutchinson Cancer Research Center)

Postdoctoral Fellow (Baylor College of Medicine)

Postdoctoral Position – Cancer Research (Weill Cornell Medical College and Cold Spring Harbor Laboratory)


Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.


Jobs are categorized regionally: United States, Canada, Europe,
Asia Pacific

Visit here to post your career opportunities.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Prostate Cell News: Archives | Events | Contact Us